On November 4, 2026, the UK Department for Business, Innovation, Science and Trade published “Guidance on the EU AI Act in Northern Ireland”. It says the Act applies in Northern Ireland “in a specific and limited way under the Windsor Framework from 10 November 2026”, following an exchange of views the UK requested in the UK-EU Withdrawal Agreement Joint Committee on April 29, 2025, which concluded on May 7, 2026, and a Joint Committee decision to add the AI Act to the Windsor Framework.
The Act applies only where an AI system is closely integrated with a tangible physical product placed on the Northern Ireland market: embedded or pre-installed when sold, or downloaded separately for a product designed to depend on it. In scope are the placing on the market of such products with prohibited AI practices (Article 5), AI literacy duties for providers (Article 4), Article 50(1) and 50(2) transparency for products such as robot pets or augmented reality glasses, high-risk obligations for Annex III systems built into products and for safety components of Annex I products such as toys, lifts and medical devices, and supply-chain duties where a third-party AI system or GPAI model is integrated into a product.
Out of scope are standalone or downloadable AI software, including AI used through a browser, app or API, the use of AI systems (with narrow exceptions for deployers of in-scope high-risk systems), and any direct obligations or codes of conduct for GPAI model providers. The guidance’s timeline puts Article 5, Article 4 and Article 50(1) at 10 November 2026, Annex III high-risk duties at 2 December 2027 and Annex I high-risk duties at 2 August 2028.
Why it matters: this is the first time any part of the EU AI Act has legal effect inside the United Kingdom. A manufacturer selling an AI-enabled toy, speaker or camera into Northern Ireland now faces EU rules that do not apply in Great Britain, while chatbots and model providers stay outside them.
What it does not show: this is government guidance, not the legal text of the Joint Committee decision, and it defers to European Commission guidance as the main technical reference. How “closely integrated” is applied to borderline products has not been tested by any regulator or court.